These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37279937)

  • 1. Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma.
    Peng X; Xia Z; Guo Y; Li Y
    Aging (Albany NY); 2023 Jun; 15(11):4889-4905. PubMed ID: 37279937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma.
    Bian Y; Bi G; Shan G; Liang J; Sui Q; Hu Z; Wang Q; Zhang Y; Fan H
    J Immunol Res; 2023; 2023():4987832. PubMed ID: 36793588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
    Li HS; Liu CM; Wang Y
    Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.
    Guo D; Wang M; Shen Z; Zhu J
    J Transl Med; 2020 Mar; 18(1):123. PubMed ID: 32143735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
    Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
    Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 8. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
    Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
    Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
    Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y
    EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
    Dai D; Shi R; Han S; Jin H; Wang X
    Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
    Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
    Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
    Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
    Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
    Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
    Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
    Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.